Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Feb 20, 2024

Analyst Presentation

Helen Giza CEO & Chair of the Management Board

Martin Fischer CFO

February 20, 2024

Q4 & FY 2023 IR Conference Call

Safe harbor statement: In this Safe harbor statement, "the Company" and "Fresenius Medical Care" refer to Fresenius Medical Care AG & Co. KGaA, a German partnership limited by shares, prior to its conversion of legal form, and to Fresenius Medical Care AG, a German stock corporation, after its conversion of legal form. This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward-looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forwardlooking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in the Company's Annual Report on Form 20-F under the headings "Forward-Looking Statements" and "Risk Factors" and under the headings in that report referred to therein, and in the Company's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care. Amounts are in Euro if not mentioned otherwise.

Implementation of measures as presented herein may be subject to information and consultation procedures with works councils and other employee representative bodies, as per local laws and practice. Consultation procedures may lead to changes on proposed measures.

Execution against strategic plan

Q4 Business Update 2

Outlook

1

3

2023 | Delivering on commitment in a year of fundamental transformation

Note: Announced divestments partly pending regulatory approval

2023 | Key developments at Group level

• Solid revenue growth at constant currency at top end of outlook
• Organic growth mainly driven by favorable business development
• Stable U.S. same market treatments¹ at center of assumed range
• Operating income (outlook base) exceeding top end of raised outlook thanks to business growth, realized FME25 savings ahead of plan and the Tricare settlement
• Successful execution on turnaround plan driving labor productivity improvements in Care Delivery and positive pricing in Care Enablement
• Several key divestments announced as part of ongoing portfolio optimization
• Cash flow strongly improved, net leverage ratio reduced to 3.2x

1 Adjusted for the exit from less profitable acute care contracts

Clinical performance on high level | Further increased NPS of 72

Quality index components

Dialysis effectiveness

Measures how sufficiently the body is cleansed of waste substances

Vascular access

Measures the share of patients who do not receive dialysis via a dialysis catheter but rather via safer vascular access alternatives that reduce risk of infection and improve outcomes

Anemia management

Measures hemoglobin levels and specific medications given during dialysis to achieve optimum clinical outcomes, such as overall health and well-being

	Q4 2023	Q3 2023
Quality index	81%	81 %
Dialysis effectiveness	94%	94%
Vascular access	77%	78%
Anemia management	72%	72%

2023 | Delivered growth against raised outlook

| outlook base¹

in € million

Organic growth

• in Care Delivery driven by value-based care business growth and higher price
• in Care Enablement driven by higher volume and price

Operating income | outlook base Revenue ¹

Margin in %

• Earnings growth driven by improved business development, realized FME25 savings, the Tricare settlement and improved labor productivity in CD
• Earnings diluted by cost inflation and Fx transaction losses in CE

1 FY 2023 €1,778 million Operating Income at cc (outlook base); reconciliation table for special items (outlook base), reported growth rates: page 29 | cc = at constant currency

2023 | Upgraded financial outlook exceeded

FY 2023 Updated Outlook FY 2023 Actuals

Revenue Low- to mid-single digit percent growth FY 2022 basis: EUR 19.4bn +5% +15% Operating income (outlook base) Between 12 and 14 percent growth FY 2022 basis: EUR 1.54bn FY 2023: EUR 20,464m FY 2023: EUR 1,778m at constant currency

Revenue and operating income, as referred to in the outlook, are both on a constant currency basis and excluding special items. Special items will be provided as separate KPI ("Revenue excluding special items", "Operating income excluding special items") to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. These items are excluded to ensure comparability of the figures presented with the Company's financial targets which have been defined excluding special items. See page 30 for reconciliation table for special items.

2023 | Key divestments announced and further under way

Portfolio optimization plan as presented

Divestments of non-core and margin dilutive assets as part of ongoing portfolio optimization plan

Closed divestments

• o CD and CE operations in Argentina
• o CD operations in Hungary
• o National Cardiovascular Partners (NCP), U.S.

Announced divestments

• o CD operations in Sub-Saharan Africa
• o Cura day hospital group, Australia
• o CD operations in Turkiye

Note: Axes are non-linear, indicative only; divestment in Hungary executed as part of FME25 program; divestment of Cura is subject to regulatory approval

2023 | Disciplined financial policy strictly followed

Deleveraging	▪ Committed to investment grade rating and to manage net financial leverage within self-imposed range of 3.0x to 3.5x. Reduced ratio from 3.4x to 3.2x. ▪ Proceeds from divestments and received Tricare settlement payment used for ongoing deleveraging
Shareholder return	▪ Proposed dividend1 of 1.19 Euro (+6% Y/Y) per share in line with1 the dividend policy
Focused investments	▪ Focus on organic growth in core portfolio ▪ Low priority on M&A activities ▪ Stringent management of capital expenditures ▪ Ambition to double ROIC by 2025

1 Pending shareholders' approval on upcoming AGM

Strategic growth drivers | Value-based care and home dialysis

Market leader transforming U.S. value-based care industry

• Premier value-based care capabilities addressing growing population of CKD and ESRD patients
  • − Market leading positioning
  • − Focus on clinical excellence including reduction in hospitalizations
  • − Increase optimal new starts to dialysis treatment
• Value-based care targets for 2024
  • − Annualized medical costs under management to grow from USD 6.5bn in 2023 to approx. 8 bn
  • − Patient lives to grow from 122k in 2023 by around 10%
  • − Revenue to grow from USD 1.4bn in 2023 to approx. 2bn
  • − Positive operating income contribution

Note: CKD = chronic kidney disease; ESRD = end-stage renal disease

Market leader further expanding U.S. home dialysis

• Accelerating shift to home dialysis
  • Higher patient satisfaction and quality of life
  • Payors favor home treatments
  • Home dialysis trend supportive of CD margin improvement
• U.S. home dialysis treatments of ~16% at end 2023
• Aspirational U.S. home dialysis treatment target of 25% by 2027

Innovation | High-Volume Hemodiafiltration now approved by FDA

CONVINCE Study

A pragmatic, multinational, randomized, controlled trial

Comparison of High-Volume Hemodiafiltration (HVHDF) versus High-Flux Hemodialysis

23% mortality rate reduction

▪ Ambition to double ROIC by 2025

With 100% adoption of HVHDF, mortality can be reduced by approximately (based on 2019 rates):

• US HD population: 3.7 deaths per 100 py
• European HD population: 1.4 deaths per 100 py

NephroCare EMEA

• >50% of patient treatments are HVHDF
• Experience with HVHDF for a decade

FME experience confirms CONVINCE results can be replicated in large patient populations¹

Critical treatment parameters of CONVINCE matched in daily routine

Survival benefits observed in CONVINCE were confirmed in FME analysis

510(k) clearance by FDA received in February 2024

• Planned broad commercial launch in 2025
• Estimated installed base of c. 160,000 in-center HD machines across all service providers in the U.S.

Note: USRDS = U.S. Renal Data System (2021 USRDS Annual Data Report - 2019 data); NephroCare mortality rates based on internal data; HVHDF = High Volume Hemodiafiltration with convection volume >23L/ treatment ¹Zhang Y et al. J Am Soc Nephrol 34: 2023; Poster TH-PO1133

Execution against strategic plan

Q4 Business Update 2

Outlook

1

3

Q4 2023 | Key developments at Group level

• Solid organic revenue growth driven by both operating segments
• Broadly stable U.S. same market treatment growth
• Operating income (outlook base) increased due to strong FME25 savings, the Tricare settlement and pricing in Care Enablement
• Realization of FME25 savings continued ahead of plan
• Value-based care business further expanded, with dilutive effect on margin

Q4 2023 | Group organic growth momentum continues

| outlook base¹

in € million

Organic growth

• in Care Delivery mainly driven by price
• in Care Enablement driven by price and volume

Operating income | outlook base Revenue ¹

Margin in %

▪ Impact from Tricare settlement compensated negative impact from our value-based care business, inflation and higher expenses related to performance-based compensation

1 Q4 2023 €579 million Operating Income at cc (outlook base); reconciliation table for special items (outlook base), reported growth rates: page 28 | cc = at constant currency

Q4 2023 | Operating margin improvement driven by Tricare settlement

Reconciliation table for special items (outlook base): page 28

Q4 2023 | Care Delivery earnings driven by savings and Tricare settlement

| outlook base¹

in € million

Operating income | outlook base Revenue ¹

1 Q4 2023 €592 million Operating Income at cc (outlook base); reconciliation table for special items (outlook base), reported growth rates: page 28 | cc = at constant currency

Q4 2023 | Care Enablement earnings driven by savings and pricing

| outlook base¹

in € million

Operating income | outlook base Revenue ¹

1 Q4 2023 €13 million Operating Income at cc (outlook base); reconciliation table for special items (outlook base), reported growth rates: page 28 | cc = at constant currency

2023 | Cash flow used to deleverage

in € million	Q4 2023	Q4 2022	FY 2023	FY 2022
Operating cash flow	719	600	2,629	2,167
▪ Capital expenditures, net	(239)	(202)	(669)	(687)
Free cash flow	480	398	1,960	1,480
▪ Free cash flow after investing activities	623	375	2,085	1,433
Total net debt and lease liabilities			10,760	11,918

Net leverage ratio (Net debt/EBITDA)

1 Excl. U.S. federal relief funding and advanced payments under the CARES Act

Key developments in FY 2023

• Operating cash flow improved by 21% mainly due positive working capital contribution and Tricare settlement
• Free cash flow conversion accelerated in line with operating cash flow and disciplined capital expenditures
• Tricare settlement proceeds of EUR 191m and divestment proceeds of EUR 135m used to deleverage
• Net leverage ratio improved toward lower end of self-imposed corridor
• Like net financial debt, total debt incl. lease liabilities was strongly reduced by EUR 1.0bn to EUR 12.2bn

Execution against strategic plan

Q4 Business Update 2

Outlook

1

3

FME25 | Savings fully on plan

• Transformation program introduced in 2021 and savings target extended to EUR 650m by 2025
• EUR 346m of sustainable savings delivered by year end 2023, while related one-time costs accumulated to EUR 420m
• Targeted savings contributions by year end 2025:

Note: Indicative illustration only; savings and costs split unaudited

Outlook | FY 2024 assumptions

Adjustments to outlook base 2023

Operating income excl. special items

in € million; all changes year-over-year

2024 outlook assumptions

• Earnings tailwinds from
  • U.S. same market treatment growth of 0.5 to 2%
  • Business growth of EUR 400-500m
  • Incremental sustainable FME25 savings of EUR 100-150m with related one-time costs of EUR 100-150m
• Earnings headwinds from
  • Higher labor costs of EUR 150-200m, mainly in CD
  • Cost inflation of EUR 100-150m, in both, CE and CD
  • Currency transaction loss of around EUR 50m, mainly in CE
• Based on EUR/USD 1.08; changes in currency translation excluded from outlook

Outlook | FY 2024 and beyond

FY 2024 Outlook Mid-term Outlook

Revenue (outlook base)	Low- to mid-single digit percent growth FY 2023 basis: EUR 19.0bn	Group operating income margin
Operating income (outlook base)	Mid- to high-teens percent growth FY 2023 basis: EUR 1.54bn	10% to 14% by 2025

Revenue and operating income, as referred to in the outlook, are both on a constant currency basis, excluding special items, the settlement agreement with the U.S. government in 2023 (Tricare) and major portfolio changes from 2023, namely Argentina and NCP. Special items will be provided as separate KPI ("Revenue excluding special items", "Operating income excluding special items") to capture effects that are unusual in nature and have not been foreseeable or not foreseeable in size or impact at the time of providing the outlook. These items are excluded to ensure comparability of the figures presented with the Company's financial targets which have been defined excluding special items. See page 29 for reconciliation table for special items.

All changes year-over-year

Questions and Answers

Appendix

Q4 2023 | Profit and Loss

	Q4 2023 € million	Q4 2022 € million	Growth in %	Growth in % cc
Revenue	4,988	4,997	0	7
Operating income	428	352	22	27
Operating income margin in %	8.6	7.0
Operating income excl. special items & PRF	555	489	14	18
Operating income margin in % excl. special items & PRF	11.1	9.8
Operating income excl. special items & PRF at cc (outlook base)1	579	489		18
Operating income margin in % excl. special items & PRF at cc	10.8	9.8
Net interest expense	85	75	12	15
Income before taxes	343	277	24	31
Income tax expense	86	83	4	13
Tax rate in %	25.2	30.0
Non-controlling interest	69	55	25	31
Net income	188	139	35	41
Net income excl. special items & PRF	259	248	4	8

1: Reconciliation table for special items (outlook base), reported growth rates: page 28 | cc = at constant currency

FY 2023 | Profit and Loss

	FY 2023 € million	FY 2022 € million	Growth in %	Growth in % cc
Revenue	19,454	19,398	0	5
Operating income	1,369	1,512	-9	-7
Operating income margin in %	7.0	7.8
Operating income excl. special items & PRF	1,741	1,540	13	15
Operating income margin in % excl. special items & PRF	8.9	7.9
Operating income excl. special items & PRF in cc (outlook base)1	1,778	1,540		15
Operating income margin in % excl. special items & PRF in cc	8.7	7.9
Net interest expense	336	292	15	16
Income before taxes	1,033	1,220	-15	-13
Income tax expense	301	325	-8	-5
Tax rate in %	29.1	26.7
Non-controlling interest	233	222	6	8
Net income	499	673	-26	-24
Net income excl. special items & PRF	756	729	4	6

1: Reconciliation table for special items (outlook base), reported growth rates: page 29 | cc = at constant currency

2022 base for 2023 targets, reconciliation adjustments

€ million	FY 2022	Q1 2022	Q2 2022	Q3 2022	Q4 2022
Revenue	19,398	4,548	4,757	5,096	4,997
Operating income	1,540	390	284	377	489

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures for comparison with outlook

	Group				Care Delivery		Care Enablement			Corporate
€ million	Q4 2023	Q4 2022	Growth rate	Q4 2023	Q4 2022	Growth rate	Q4 2023	Q4 2022	Growth rate	Q4 2023	Q4 2022
Operating Income	428	352	22%	515	456	13%	-42	-62	-32%	-44	-44
FME25 program	52	95		25	63		27	32		--	--
Ukraine war	--	25		--	-2		--	27		--	--
Humacyte investment remeasurement	1	24		--	--		--	--		1	24
Hyperinflation Turkiye	--	-1		--	-1		0	0		--	--
Legacy portfolio optimization	57	--		32	--		25	--		0	--
Legal form conversion costs	17	--		--	--		--	--		17	--
Net gain related to Interwell Health	--	0		--	0		--	--		--	--
U.S. Provider Relief Funding	--	-6		--	-6		--	--		--	--
Operating income excl. special items and PRF	555	489	14%	572	510	12%	10	-3	n.a.	-26	-20
Foreign currency translation	24	--	--	20	--	--	3	--	--	1	--
Operating income excl. special items and PRF in cc	579	489	18%	592	510	16%	13	-3	n.a.	-25	-20

Inter-segment elimination effect on operating income: €-1m in Q4 2023, €2m in Q4 2022 | cc = at constant currency

2022 base for 2023 targets, reconciliation adjustments

€ million	FY 2022	Q1 2022	Q2 2022	Q3 2022	Q4 2022
Revenue	19,398	4,548	4,757	5,096	4,997
Operating income	1,540	390	284	377	489

Reconciliation of non-IFRS financial measures to the most directly comparable IFRS financial measures for comparison with outlook

	Group			Care Delivery			Care Enablement				Corporate
€ million	FY 2023	FY 2022	Growth rate	FY 2023	FY 2022	Growth rate	FY 2023	FY 2022	Growth rate	FY 2023	FY 2022
Operating Income	1,369	1,512	-9%	1,516	1,686	-10%	-67	-30	123%	-67	-144
FME25 program	153	204		75	118		78	86		0	--
Ukraine war	--	49		--	9		--	40		--	--
Humacyte investment remeasurement	-15	103		--	--		--	--		-15	103
Hyperinflation Turkiye	--	5		--	-2		--	7		--	--
Legacy portfolio optimization	204	--		96	--		108	--		--	--
Legal form conversion costs	30	--		--	--		--	--		30	--
Net gain related to Interwell Health	--	-56		--	-56		--	--		--	--
U.S. Provider Relief Funding	--	-277		--	-277		--	--		--	--
Operating income excl. special items and PRF	1,741	1,540	13%	1,687	1,478	14%	119	103	16%	-52	-41
Foreign currency translation	37	--	--	35	--	--	5	--	--	-3	--
Operating income excl. special items and PRF in cc	1, 778	1,540	15%	1,722	1,478	16%	124	103	19%	-55	-41

Inter-segment elimination effect on operating income: €-13m in FY 2023, €0m in FY 2022 | cc = at constant currency

Reconciliation of non-IFRS financial measures to most directly comparable IFRS financial measures

	FY 2023 € million	FY 2022 € million	FY 2021 € million
Debt
Short-term debt from unrelated parties	457	644	1,178
+ Short-term debt from related parties	-	4	78
+ Current portion of long-term debt	487	694	668
+ Current portion of lease liabilities from unrelated parties	593	650	640
+ Current portion of lease liabilities from related parties	24	24	21
+ Long-term debt, less current portion	6,960	7,171	6,647
+ Lease liabilities from unrelated parties, less current portion	3,419	3,875	3,990
+ Lease liabilities from related parties, less current portion	110	130	98
+ Debt and lease liabilities included within liabilities directly associated with assets held for sale	137	-	-
Total debt and lease liabilities	12,187	13,192	13,320
− Cash and cash equivalents	-1,427	-1,274	-1,482
Total net debt and lease liabilities	10,760	11,918	11,838

Includes cash and cash equivalents included within assets held for sale.

Reconciliation of adjusted EBITDA and net leverage ratio to the most directly comparable IFRS financial measures

	FY 2023 € million	FY 2022 € million	FY 2021 € million
Net income	732	895	1,219
+ Income tax expense	301	325	353
− Interest income	-88	-68	-73
+ Interest expense	424	360	353
+ Depreciation and amortization	1,613	1,718	1,586
Adjustments1 +	409	320	125
Adjusted EBITDA	3,391	3,550	3,563
Net leverage ratio (Net debt/EBITDA)	3.2	3.4	3.3

1 Adjustments: Acquisitions and divestitures made for the last twelve months with a purchase price above a €50 M threshold as defined in the Syndicated Credit Facility (2023: -€35 M; 2022: -€22 M), non-cash charges, primarily related to pension expense (2023: €56 M; 2022: €54 M), impairment loss (2023: €139 M; 2022: €120 M) and special items, including costs related to the FME25 Program (2023: €106 M; 2022: €155 M), Legal Form Conversion Costs (2023: €30 M), Legacy Portfolio Optimization (2023: €128 M), Humacyte Investment Remeasurement (2023: -€15 M; 2022: €103 M), Net Gain Related to InterWell Health (2022: -€114 M), Hyperinflation in Turkiye (2022: €5 M) and the Impacts Related to the War in Ukraine (2022: €19 M).

Return on Invested Capital (ROIC) continued to be impacted by lower earnings

• For the years 2015-17 ROIC as reported within the Form 20-F.
• ROIC adjusted in 2018 for the divestiture of Care Coordination activities, FCPA-related charge, U.S. Ballot Initiatives, U.S. tax reform / including these effects, ROIC for FY 2018 was 12.4%
• ROIC adjusted in 2019 for the effects of IFRS 16, NxStage, FCPA, Cost optimization costs, divestiture of Care Coordination activities / including these effects, ROIC for FY 2019 was 6.8% (excl. IFRS 16)
• ROIC in 2020 excl. the impact of the Latin America impairment (special item) and in 2021 excluding FME25 (special item)
• ROIC for 2020 and 2021 was 7.5% and 5.5% excl. IFRS 16 and excl. Latin America impairment in 2020
• ROIC in 2022 adjusted for the effects of the FME25 program, the Humacyte Investment Remeasurement, the net gain related to InterWell Health, the effects of hyperinflation in Turkiye and impacts related to the war in Ukraine
• ROIC in 2023 adjusted for the effects of the FME25 program, Legal Form Conversion Costs, Legacy Portfolio Optimization and Humacyte Investment Remeasurement

Exchange rates, U.S. dialysis days per quarter, definitions

Exchange rates

		FY 2023	FY 2022	FY 2021
€:USD	Period end	1.105	1.067	1.133
	Average	1.081	1.053	1.183
€:CNY	Period end	7.851	7.358	7.195
	Average	7.660	7.079	7.628
€:RUB	Period end	100.215	78.138	85.300
	Average	92.461	73.365	87.153
€:ARS	Period end	894.735	189.201	116.780
	Average	315.018	137.041	112.522
€:BRL	Period end	5.362	5.639	6.310
	Average	5.401	5.440	6.378
€:TRL	Period end	32.653	19.965	15.234
	Average	25.760	17.409	10.512

U.S. dialysis days per quarter

	Q1	Q2	Q3	Q4	Full year
2023	77	78	79	78	312
2022	77	78	79	79	313
2021	77	78	79	79	313

Definitions

cc	At constant currency
HD	Hemodialysis
PD	Peritoneal dialysis
Net income	Net income attributable to shareholders of FME
LTM	Last-Twelve-Months

Patients, treatments, clinics

	as of December 31, 2023			as of December 31, 2022
	Patients	Treatments	Clinics	Patients	Treatments	Clinics
United States	205,308	31,210,375	2,615	206,033	31,361,555	2,671
Growth in %	0	0	-2	0	-2	0
International	127,240	20,444,165	1,310	138,654	20,948,576	1,445
Growth in %	-8	-2	-9	-1	0	-3
Total	332,548	51,654,540	3,925	344,687	52,310,131	4,116
Growth in %	-4	-1	-5	0	-1	-1

Segment information for FY 2021, 2022 and 2023

€ million; % change year-over-year	FY 2023	Growth	Growth at cc	Organic growth	FY 2022	Growth	Growth at cc	Organic growth	FY 2021
Total
Revenue	19,454	0	5	4	19,398	10	2	2	17,619
Operating income	1,369	-9	-7		1,512	-18	-25		1,852
Operating income margin in %	7.0				7.8				10.5
Operating income excl. special items	1,741	13	15		1,540	-20	-26		1,915
Operating income margin in % excl. special items	8.9				7.9				10.9
Care Delivery segment
Revenue	15,578	0	5	3	15,593	11	2	1	14,031
Operating income	1,516	-10	-8		1,686	3	-8		1,643
Operating income margin in %	9.7				10.8				11.7
Operating income excl. special items	1,687	14	16		1,478	-13	n.a.		1,693
Operating income margin in % excl. special items	10.8				9.5				12.1
Care Enablement segment
Revenue	5,345	0	5	4	5,353	5	0	0	5,086
Operating income	-67	123	123		-30	--	--		315
Operating income margin in %	-1.2				-0.6				6.2
Operating income excl. special items	119	15	19		103	-68	n.a.		327
Operating income margin in % excl. special items	2.2				1.9				6.4
Inter-segment elimination
Revenue	-1,469	-5	0		-1,548	3	-4		-1,498
Operating income	-13	--	--		0	--	--		7
Corporate
Operating income	-67	-54	-52		-144	29	14		-113
Operating income excl. special items	-52	26	33		-41	-63	n.a.		-112

Note: cc = constant currency; n. a. = not available

Financial calendar

Date		Event
g n rti M & G o A p e R	February 20, 2024 May 7, 2024 May 16, 2024 July 30, 2024 November 5, 2024	Report on 4th quarter 2023: Earnings Release and Conference Call Report on 1st quarter 2024: Earnings Release and Conference Call Annual General Meeting 2024, Frankfurt Report on 2nd quarter 2024: Earnings Release and Conference Call Report on 3rd quarter 2024: Earnings Release and Conference Call
s s e w c o n h e & s r e d nf a o o R C	February 21-22, 2024 February 21, 2024 February 26, 2024 February 27, 2024 March 11, 2024 March 12-13, 2024 March 26, 2024 March 27, 2024 April 3-4, 2024	FY 2023 CEO & CFO Roadshow, London Sellside Analyst Reception, London Morgan Stanley European MedTech & Life Sciences Conference, London UBS European Healthcare Conference, London U.S. investor clinic visit, Miami Barclays Global Healthcare Conference 2024, Miami BNPP Exane Healthcare Conference, Virtual Société Générale Flagship ESG Conference, Paris CEO U.S. Roadshow, Boston and NYC

Dates and/or participation might be subject to change

Contacts

Fresenius Medical Care AG Investor Relations Else-Kröner-Str. 1 61352 Bad Homburg v. d. H. Germany

ir@freseniusmedicalcare.com

Ticker: FME or FMS (NYSE/ADR)

WKN: 578 580

ISIN: DE00057858002

CUSIP (ADR): 358029106

Dr. Dominik Heger

Head of Investor Relations and Head of Investor Relations, Strategic Development & Communications | EVP

+49(0) 6172-609-2525

dominik.heger@ freseniusmedicalcare.com

Ilia Kuerten

Vice President Investor Relations

+49(0) 6172-268 5966

ilia.kuerten@ freseniusmedicalcare.com

Alicia Cahill

Senior Director Investor Relations

+1 860-609-2394

alicia.cahill@ freseniusmedicalcare.com